arrow
T

Takaya Shimura

nagoya city university graduate school of medical sciences
H指数:29
被引数:2,937

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Increased Lymphocyte Proportions as a Candidate Biomarker for Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy

淋巴细胞比例升高作为免疫检查点抑制剂联合化疗治疗患者中免疫相关不良事件的候选生物标志物

2026-10-070
OAAI
A prospective study of duodenal laparoscopy-endoscopy cooperative surgery for superficial duodenal tumors, including periampullary and medial wall lesions

一项关于腹腔镜-内镜联合手术治疗浅表性十二指肠肿瘤(包括壶腹周围和侧壁病变)的前瞻性研究

2025-09-130
PREAI
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

含Ramucirumab的化疗方案用于对铂类为基础的化疗方案耐药/不耐受的胃肠道神经内分泌癌患者的疗效:一项多中心观察性回顾研究(WJOG13420G)

2025-07-230
OAAI
Lysosomal Cathepsin S Escape Facilitates Near Infrared Light-Triggered Pyroptosis Via an Antibody-Indocyanine Green Conjugate

陈,F.,田,X. F.,杨,T.,戴,Y. J.,陈,D. Y.,陈,H. B.,等。(2025a)。溶酶体半胱天冬酶S逃逸通过抗体-吲哚菁绿缀合物促进近红外光触发的焦亡。Adv. Sci. e04851。doi:10.1002/advs.202504851

2025-06-200
OAAI
Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody

JACCRO CC-16研究的最终分析:Ramucirumab联合FOLFIRI方案用于对EGFR抗体耐药的RAS野生型mCRC患者

2024-09-010
PRE